By Michele Maatouk
Date: Thursday 25 Jun 2026
(Sharecast News) - Germany's Merck KGaA said on Thursday that it has agreed to buy Minneapolis-based biotech company Bio-Techne for around $11.3bn.
Under the terms of the deal, Merck will pay $73 per share in cash, which is a 24% premium to Bio-Techne's closing share price on Wednesday.
Bio-Techne is...
or login to read the full story
Email this article to a friend
or share it with one of these popular networks:
You are here: news